{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and \\>0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).","groups":[{"description":"Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG000","title":"CML-CP With Prior Imatinib Only"},{"description":"Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG001","title":"CML-AP With Prior Imatinib Only"},{"description":"Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG002","title":"CML-CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All participants who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"Up to End of the Treatment (Approximately 7.5 years)","title":"Number of Participants With Overall Major Cytogenetic Responses (Phase II)","type":"SECONDARY","unitOfMeasure":"participants"}